Unilife Corp. has appointed four senior executives to its commercial development team. Mr. Alan Shortall, chief executive officer of Unilife, said, "Unilife has established a broad and market-driven portfolio of injectable drug delivery systems. The Unilife commercial pipeline is growing with many pharmaceutical companies seeking to utilize our innovative, differentiated devices to enable and enhance their injectable therapies. These commercial opportunities are advancing towards the signing of new development or commercial supply agreements.”
"Driven by the rapid growth of our customer engagements and increasing pace of customer interactions, and in full accordance with our business plan, I am pleased to announce the addition of four new senior executives to our commercial development team. These new appointments include some of the most experienced, highly respected commercial development professionals in the drug delivery device industry,” said Mr. Shortall.
"With more than 80 years of combined experience among them, these executives are joining Unilife because they recognize the commercial opportunity of our broad device portfolio and capability to serve pharmaceutical customers with speed, agility and reliability. They recognize that our customer-driven model for injectable drug delivery systems is the way of the future. I fully expect that our expanded commercial development team will not only strengthen many of Unilife's existing customer relationships, but also generate many new commercial opportunities in the months and years ahead," Mr. Shortall added.